Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Heart Test Laboratories Inc. Warrant (HSCSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: HSCSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.5% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.58 | 52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 |
52 Weeks Range 0.04 - 0.17 | Updated Date 03/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.95% | Return on Equity (TTM) -163.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 995735 |
Shares Outstanding - | Shares Floating 995735 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Heart Test Laboratories Inc. Warrant
Company Overview
History and Background
Heart Test Laboratories, Inc. (HSCS) focuses on the development and commercialization of cardiovascular diagnostic technologies. The warrants are tied to the underlying common stock. Details on the founding year and evolution specifics related to the warrant itself are not readily available as it's derived from the company's public offering.
Core Business Areas
- Electrocardiographic (ECG) Testing: Development of MyoVistau00ae ECG device for detection of heart disease. This is the primary focus.
Leadership and Structure
The leadership structure includes a Board of Directors and executive management team. Specific details beyond this general structure aren't widely available for the warrant itself.
Top Products and Market Share
Key Offerings
- Heart Test Laboratories Inc. Warrant: The warrants represent the right to purchase shares of HSCS common stock at a specified price. Its value is derived entirely from the underlying common stock. Competitors are other cardiovascular diagnostic companies. Market share data not applicable to the warrant directly as it is derived from the common stock.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is driven by an aging population and rising incidence of heart disease.
Positioning
Heart Test Laboratories aims to disrupt the traditional ECG market with its MyoVistau00ae device.
Total Addressable Market (TAM)
The global cardiovascular diagnostic and monitoring market is estimated to be in the billions. Heart Test Laboratories' positioning hinges on capturing a share of this market with their MyoVista device (underlying the warrant value).
Upturn SWOT Analysis
Strengths
- Potential for innovative ECG technology (MyoVista).
- Addresses a significant market need.
Weaknesses
- Reliance on successful commercialization of MyoVista.
- Limited operating history.
- Dependence on capital markets for funding.
Opportunities
- Expanding MyoVista to new markets.
- Partnerships with healthcare providers.
- Technological advancements in cardiovascular diagnostics.
Threats
- Competition from established medical device companies.
- Regulatory hurdles.
- Technological obsolescence.
Competitors and Market Share
Key Competitors
- GE
- PHG
- SIEMENS
Competitive Landscape
Heart Test Laboratories competes with larger, established medical device companies. They aim to differentiate with their novel technology (MyoVista).
Growth Trajectory and Initiatives
Historical Growth: Growth is linked to the commercial success of MyoVista.
Future Projections: Projections dependent on adoption rate of MyoVista and overall market growth in cardiac diagnostics.
Recent Initiatives: Focus on regulatory approvals and commercial partnerships for MyoVista.
Summary
Heart Test Laboratories Inc. Warrant (HSCSW) is a derivative tied to a company focused on novel cardiac diagnostic technology. The warrant's value hinges heavily on the success of their MyoVista ECG device. Commercialization execution and securing partnerships are key for their growth. Competition in the medical device space is intense, posing a considerable challenge. A successfull commercialization will result in rapid expansion.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC).
- Industry reports.
- Analyst estimates.
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The value of the warrant is extremely speculative and sensitive to the common stock price and news.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Warrant
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.